You are here

Home

Who We Are

Dmitri Beglov, Ph.D.
President, Acpharis Inc.

Dmitri Beglov is the President of Acpharis Inc., and a senior research scientist in the Department of Biomedical Engineering at Boston University. Prior to joining Boston University, he acquired eight years of industrial experience as a developer of commercial molecular simulation software such as CHARMM and MBO(N)D. Working with Dr. Vajda, Dr. Beglov was one of the key developers of the computational fragment mapping program FTMap, and of the protein docking program Piper.
David Hall, Ph.D
Chief Executive Officer

David Hall is Acpharis's first employee. He received his PhD in Biomedical Engineering from Boston University in 2012 where he performed research on incorporating side chain flexibility into FFT-based sampling methods for protein-protein docking and computational solvent mapping. He has published several prominent papers in JACS and PNAS on applications of Acpahris's technologies to traditional and protein-protein interaction drug targets.
Sandor Vajda, Ph.D.
Chief Science Officer, Acpharis Inc.
Professor of Biomedical Engineering, Boston University

Sandor Vajda is Professor of Biomedical Engineering and Chemistry, and the director of the Biomolecular Engineering Research Center at Boston University. His research focuses on two important biological problems, i.e., the modeling of protein-protein interactions and the development of computational tools for drug design. In 2004 Dr. Vajda and his graduate students founded SolMap Pharmaceuticals, Cambridge, MA, a start-up company focusing on fragment-based drug design. SolMap was acquired by Forma Therapeutics, Cambridge, MA, in 2008.
Dima Kozakov, Ph.D.
Chief Technology Officer, Acpharis Inc.
Research Assistant Professor, Boston University

Dima Kozakov received an M.S. in Applied Mathematics and Physics in Moscow Institute of Physics and Technology, and PhD in Biomedical Engineering at Boston University. Currently he is Research Assistant Professor of Biomedical Engineering at Boston University. Dr. Kozakov has been active in method development for modeling of biological macromolecules, with emphasis on molecular interactions and drug design. Dr. Kozakov (with Dr. Vajda) has developed protein docking methods that were ranked the best in the latest evaluation of the worldwide blind protein docking experiment CAPRI. His research has been funded by the National Institute of General Medical Sciences.